Weight loss and decrease in hyperglycemia and IR, which are induced by treatment of obese PCOS patients with GLP-1 receptor agonists, lead to a decrease in HA [167,168,169] and an improvement in menstrual frequency [167,169]. This evidence concerns the gene GLP1R and polycystic ovary syndrome.